CTOR · Citius Oncology, Inc.

Citius Oncology, Inc. faces a material regulatory risk stemming from its failure to satisfy Nasdaq’s minimum bid price requirement, a condition tied directly to market perception of financial viability and investor confidence. The violation—sustained sub-$1.00 bid pricing over 30 consecutive business days—triggers a formal, time-bound remediation process rather than immediate delisting. The 180-day compliance window ending October 19, 2026 provides operational flexibility, but the Company must achieve a sustained price recovery (ten consecutive business days at or above $1.00) or execute a structural remedy such as a reverse stock split. Eligibility for a second compliance period is conditional—not automatic—and requires concurrent satisfaction of other listing standards, including market value of publicly held shares, which introduces additional execution risk. While the notice has no immediate effect on trading or listing status, prolonged non-compliance threatens liquidity, institutional eligibility, and access to capital markets. The Company’s statement that it is ‘evaluating its options’ without disclosing specific remedial plans or board-level actions signals uncertainty in execution path, heightening investor scrutiny around near-term corporate governance and capital structure decisions.